Life Sciences: China
Sidley has a powerful, fully integrated Life Sciences practice in China serving multinational pharmaceutical, biotechnology, medical device and food companies in every aspect of their business operations. Sidley's experience in foreign direct investments (FDI), commercial corporate/M&A, licensing and joint ventures, China anti-bribery/U.S. FCPA compliance, antitrust, intellectual property and local enforcement work, as well as our regulatory experience, allows us to advise on virtually every facet of life sciences operations in China.
“This firm has a superb reputation among peers and clients in the market, and earns particular praise for its formidable regulatory experience. It offers a full-service and dedicated life sciences team, which advises on US Foreign Corrupt Practices Act/anti-bribery, clinical trials, product recalls, M&A, joint ventures, antitrust and IP matters, among others. As a global practice it is well versed in US and EU industry practices, and prominent clients include major multinationals such as GlaxoSmithKline, Baxter, Hoffmann-La Roche, Merck and Pfizer. Sources say: ‘They really are experts in this area, and were able to advise in a very precise and practical manner.’ ‘They have a deep understanding of the industry from both a regulatory and M&A point of view. Rather than providing simple legal advice they will fulfil clients' needs by finding a solution.’ ”
Chambers Asia, 2012
Sidley was the first international law firm to establish a stand-alone, comprehensive food and drug regulatory practice in China. As an integral part of our Global Life Sciences practice, we bring our knowledge of industry practices in the U.S. and EU to each project in China and help develop global Standard Operating Procedures (SOPs) and benchmark best practices.
We assist Chinese drug and device regulatory agencies in training programs on a broad range of topics. Sidley is also the first law firm to have been honored with a Memorandum of Understanding (MOU) issued by the Shanghai Institute for Food and Drug Safety in January 2008, under which Sidley provides input in the formulation of new drug and device laws and sponsors annual drug safety seminars for international audiences.
“While Sidley Austin offers a full spectrum of services in this field, it is particularly strong in regulatory compliance in the food and drug sector. It also excels in advising clients on corporate and commercial activity related to the life sciences industry, including strategic alliances, acquisitions and pharmacovigilance due diligence. Sources say: ‘This firm has in-depth, technical knowledge of life sciences, and this is a key factor in its success.’”
Chambers Asia 2011
Sidley Updates
News & Media
Publications